Description
Goldline Pharmaceutical Limited (ticker: 544759) will be added to the BSE SME IPO Index effective May 20, 2026, following its listing on BSE on May 19, 2026.
Summary
BSE Index Services Private Limited has announced the addition of Goldline Pharmaceutical Limited (Exchange Ticker: 544759) to the BSE SME IPO Index. The stock is being listed on BSE effective May 19, 2026, and will be included in the index at the open of May 20, 2026.
Key Points
- Goldline Pharmaceutical Limited (ticker: 544759) is newly listed on BSE effective May 19, 2026
- The stock will be added to the BSE SME IPO Index effective at open of May 20, 2026
- This addition is referenced from Notice No. 20260518-28
- The corporate action has been included in the end-of-day corporate action file (*.SDE) dated May 19, 2026
- Queries can be directed to bseindex@bseindia.com
Regulatory Changes
No regulatory changes. This is a routine index composition update following a new SME IPO listing.
Compliance Requirements
No direct compliance requirements for market participants. Index-tracking funds and ETFs benchmarked to the BSE SME IPO Index should update their portfolios to include Goldline Pharmaceutical Limited at the open of May 20, 2026.
Important Dates
- May 19, 2026: Goldline Pharmaceutical Limited listed on BSE
- May 20, 2026: Effective date of addition to BSE SME IPO Index (at market open)
- May 19, 2026 (end of day): Corporate action reflected in the *.SDE file
Impact Assessment
Limited market impact. This is a standard index inclusion event for a newly listed SME IPO stock. The primary impact is on passive funds and portfolios that track the BSE SME IPO Index, which will need to include this stock from May 20, 2026. No broader market or regulatory implications are expected.
Impact Justification
Routine index addition for a newly listed SME IPO stock; affects only passive investors tracking the BSE SME IPO Index.